Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIM HIGH: Niacin Plus Statin to Prevent Vascular Events.

Trial Profile

AIM HIGH: Niacin Plus Statin to Prevent Vascular Events.

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Niacin (Primary) ; Ezetimibe; Simvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms AIM-HIGH
  • Sponsors Axio Research Corporation
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Nov 2016 Post-hoc analysis results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 29 Mar 2016 Results published in the American Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top